American Heart Journal
Volume 151, Issue 3 , Pages 571-579 , March 2006

Optimizing outcomes in the patient with acute decompensated heart failure

  • Mandeep R. Mehra, MD

      Affiliations

    • Corresponding Author InformationReprint requests: Mandeep R. Mehra, MD, University of Maryland School of Medicine, 22 South Green Street, Room S3B06, Baltimore, MD 21201.

Received 17 October 2004 ,Accepted 29 April 2005.

References 

  1. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Circulation. 2001;104:2996–3007
  2. Aghababian RV. Acutely decompensated heart failure: opportunities to improve care and outcomes in the emergency department. Rev Cardiovasc Med. 2002;3(Suppl 4):S3–S9
  3. Graves EJ, Kozak LJ. National Hospital Discharge Survey: Annual Summary, 1996. Vital Health Stat. 1999;1–46[Series 13]
  4. Fonarow GC for the ADHERE Scientific Advisory Committee. The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med. 2003;4(Suppl 7):S21–S30
  5. Jong P, Vowinckel E, Liu PP, et al. Prognosis and determinants of survival in patients newly hospitalized for heart failure: a population-based study. Arch Intern Med. 2002;162:1689–1694
  6. Fonarow GC. Pharmacologic therapies for acutely decompensated heart failure. Rev Cardiovasc Med. 2002;3(Suppl 4):S18–S27
  7. Nohria A, Lewis E, Stevenson LW. Medical management of advanced heart failure. JAMA. 2002;287:628–640
  8. Peacock WF. Rapid optimization: strategies for optimal care of decompensated congestive heart-failure patients in the emergency department. Rev Cardiovasc Med. 2002;3(Suppl 4):S41–S48
  9. Lee DS, Austin PC, Rouleau JL, et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003;290:2581–2587
  10. Fonarow GC, Adams KF, Abraham WT, et al. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA. 2005;293:572–580
  11. Horwich TB, Patel J, MacLellan WR, et al. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation. 2003;108:833–838
  12. Stevenson LW, Tillisch JH, Hamilton M, et al. Importance of hemodynamic response to therapy in predicting survival with ejection fraction ≤20% secondary to ischemic or nonischemic dilated cardiomyopathy. Am J Cardiol. 1990;66:1348–1354
  13. Drazner MH, Rame JE, Stevenson LW, et al. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. N Engl J Med. 2001;345:574–581
  14. Myers J, Gullestad L, Vagelos R, et al. Clinical, hemodynamic, and cardiopulmonary exercise test determinants of survival in patients referred for evaluation of heart failure. Ann Intern Med. 1998;129:286–293
  15. Ferguson DW, Berg WJ, Sanders JS. Clinical and hemodynamic correlates of sympathetic nerve activity in normal humans and patients with heart failure: evidence from direct microneurographic recordings. J Am Coll Cardiol. 1990;16:1125–1134
  16. Nohria A, Tsang SW, Fang JC, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol. 2003;41:1797–1804
  17. Cody RJ. Clinical trials of diuretic therapy in heart failure: research directions and clinical considerations. J Am Coll Cardiol. 1993;22(Suppl A):165A–171A
  18. Gottlieb SS, Brater DC, Thomas I, et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation. 2002;105:1348–1353
  19. Kubo SH, Clark M, Laragh JH, et al. Identification of normal neurohormonal activity in mild congestive heart failure and stimulating effect of upright posture and diuretics. Am J Cardiol. 1987;60:1322–1328
  20. Krämer BK, Schweda F, Riegger GAJ. Diuretic treatment and diuretic resistance in heart failure. Am J Med. 1999;106:90–96
  21. Cotter G, Metzkor E, Kaluski E, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet. 1998;351:389–393
  22. Mehta RL, Pascual MT, Soroko S, et al. Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA. 2002;288:2547–2553
  23. Salvador DR, Rey NR, Ramos GC, et al. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev. 2004;CD003178
  24. Cosin J, Diez J. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail. 2002;4:507–513
  25. Tsutamoto T, Sakai H, Wada A, et al. Torasemide inhibits transcardiac extraction of aldosterone in patients with congestive heart failure. J Am Coll Cardiol. 2004;44:2252–2253
  26. Burger AJ, Horton DP, LeJemtel T, et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT Study. Am Heart J. 2002;144:1102–1108
  27. Ewy GA. Inotropic infusions for chronic congestive heart failure. Medical miracles or misguided medicinals?. J Am Coll Cardiol. 1999;33:572–575
  28. Cuffe MS, Califf RM, Adams KFJ, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287:1541–1547
  29. Abraham WT, Adams KF, Fonarow GC, et al. Comparison of in-hospital mortality in patients treated with nesiritide vs. other parenteral vasoactive medications for acutely decompensated heart failure: an analysis from a large prospective registry database. [Abstract 298] J Card Fail. 2003;9(Suppl 1):S81
  30. Burger MR, Burger AJ. Nesiritide: a promising new drug for the treatment of decompensated heart failure. Heart Drug. 2002;2:39–46
  31. Peacock F, Emerman CL, Costanzo MR, et al. Early initiation of intravenous vasoactive therapy improves heart failure outcomes: an analysis from the ADHERE registry database. [Abstract 92] Ann Emerg Med. 2003;42(4 Suppl):S26
  32. Publication Committee  for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531–1540
  33. Elkayam U, Akhter MW, Singh H, et al. Comparison of effects on left ventricular filling pressure of intravenous nesiritide and high-dose nitroglycerin in patients with decompensated heart failure. Am J Cardiol. 2004;93:237–240
  34. Kloner RA, Hutter AM, Emmick JT, et al. Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol. 2003;42:1855–1860
  35. Abraham WT, Lowes BD, Ferguson DA, et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail. 1998;4:37–44
  36. Marcus LS, Hart D, Packer M, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation. 1996;94:3184–3189
  37. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med. 2000;343:246–253
  38. Aronson D, Burger AJ. Intravenous nesiritide (human B-type natriuretic peptide) reduces plasma endothelin-1 levels in patients with decompensated congestive heart failure. Am J Cardiol. 2002;90:435–438
  39. Yoshimura M, Yasue H, Morita E, et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation. 1991;84:1581–1588
  40. Burger AJ, Elkayam U, Neibaur MT, et al. Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy. Am J Cardiol. 2001;88:35–39
  41. Silver MA, Horton DP, Ghali JK, et al. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol. 2002;39:798–803
  42. de Lissovoy G, Stier DM, Ciesla G, et al. Economic implications of nesiritide versus dobutamine in the treatment of patients with acutely decompensated congestive heart failure. Am J Cardiol. 2003;92:631–633
  43. Lenz TL, Foral PA, Malesker MA, et al. Impact of nesiritide on health care resource utilization and complications in patients with decompensated heart failure. Pharmacotherapy. 2004;24:1137–1146
  44. Peacock WF, Emerman CL, Wynne J, et al. Early use of nesiritide in the emergency department is associated with improved outcome: an ADHERE registry analysis. Ann Emerg Med. 2004;44(Suppl 4):S78
  45. Gattis WA, O'Connor CM. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure. Am J Cardiol. 2004;93(Suppl):74B–76B
  46. Emerman CL. Safety and efficacy of nesiritide for the treatment of decompensated heart failure. Rev Cardiovasc Med. 2002;3(Suppl 4):S28–S34
  47. Butler J, Emerman C, Peacock WF, et al. The efficacy and safety of B-type natriuretic peptide (nesiritide) in patients with renal insufficiency and acutely decompensated congestive heart failure. Nephrol Dial Transplant. 2004;19:391–399
  48. Yancy CW. Nesiritide is safe for CHF patients with renal insufficiency: retrospective results from the Follow Up Serial Infusions of Nesiritide (FUSION) trial. [Abstract 359] J Card Fail. 2004;10(Suppl):S114
  49. Wang DJ, Dowling TC, Meadows D, et al. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation. 2004;110:1620–1625
  50. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487–1491
  51. Palmer BF. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what to do if the serum creatinine and/or serum potassium concentration rises. Nephrol Dial Transplant. 2003;18:1973–1975
  52. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor–associated elevations in serum creatinine: is this a cause for concern?. Arch Intern Med. 2000;160:685–693
  53. Epstein BJ. Elevations in serum creatinine concentration: concerning or reassuring?. Pharmacotherapy. 2004;24:697–702
  54. Sackner-Bernstein JD, Kowalski M, Fox M, et al. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA. 2005;293:1900–1905
  55. Tovar JM, Gums JG. Tezosentan in the treatment of acute heart failure. Ann Pharmacother. 2003;37:1877–1883
  56. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002;360:196–202
  57. Del Carlo CH, O'Connor CM. Cardiac troponins in congestive heart failure. Am Heart J. 1999;138:646–653
  58. Pfister R, Scholz M, Wielckens K, et al. Use of NT-proBNP in routine testing and comparison to BNP. Eur J Heart Fail. 2004;6:289–293
  59. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol. 2001;37:379–385
  60. Kazanegra R, Cheng V, Garcia A, et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Card Fail. 2001;7:21–29
  61. Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol. 2001;37:386–391
  62. Maisel A. B-type natriuretic peptide measurements in diagnosing congestive heart failure in the dyspneic emergency department patient. Rev Cardiovasc Med. 2002;3(Suppl 4):S10–S17
  63. Bhalla V, Willis S, Maisel AS. B-type natriuretic peptide: the level and the drug—partners in the diagnosis and management of congestive heart failure. Congest Heart Fail. 2004;10:3–27
  64. Shah MR, O'Connor CM, Sopko G, et al. Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE): design and rationale. Am Heart J. 2001;141:528–535
  65. Connors AFJ, Speroff T, Dawson NV, et al. The effectiveness of right heart catheterization in the initial care of critically ill patients. JAMA. 1996;276:889–897
  66. National Heart, Lung, and Blood Institute. No increase in deaths or hospitalizations for heart failure patients who have a pulmonary artery catheter. Source: National Institute of Health website. Updated: November 9, 2004, Accessed: February 22, 2005.
  67. Yancy C, Abraham WT. Noninvasive hemodynamic monitoring in heart failure: utilization of impedance cardiography. Congest Heart Fail. 2003;9:241–250

PII: S0002-8703(05)00513-2

doi: 10.1016/j.ahj.2005.04.034

American Heart Journal
Volume 151, Issue 3 , Pages 571-579 , March 2006

Article Tools

* Image Usage & Resolution